We hypothesise however, that in luminal-type/ER+/LN− breast cancer, AREG expression downstream of ERα-CITED1 may be associated with an active ERα-coregulator complex that is more amenable to endocrine antagonism. Here, CITED1 is linked to breast carcinoma.